

**For immediate release**

## CONJUCHEM INC. COMPLETES \$15.75 MILLION FINANCING

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

**MONTREAL, Canada, May 18, 2006** – ConjuChem Inc. (TSX: CJC) today announced that it has closed its previously announced bought deal of 7,500,000 Common Shares at a price of \$2.10 per Common Share, for gross proceeds of \$15,750,000.

The Company entered into an underwriting agreement with Sprott Securities Inc. and Orion Securities Inc. as co-lead underwriters on behalf of a syndicate of underwriters on May 3, 2006. The proceeds of the financing are intended for the advancement of the Company's PC-DAC<sup>TM</sup>:Exendin-4 and DAC<sup>TM</sup>:GRF compounds, the advancement of other products under development, as well as general corporate purposes.

“This financing provides us the financial strength to build value and deliver on key milestones throughout 2006 in our lead programs, PC-DAC<sup>TM</sup>:Exendin-4 and DAC<sup>TM</sup>:GRF,” said Vice President and CFO Lennie Ryer.

These securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

In addition, it is expected that the corporate reorganization involving, among others, ConjuChem Biotechnologies Inc. and ConjuChem Inc. described in detail in the management proxy circular of ConjuChem Inc. dated April 13, 2006 and for which securityholder approval was obtained on May 12, 2006 will be completed on May 23, 2006.

### **About ConjuChem**

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC<sup>TM</sup> and PC-DAC<sup>TM</sup> Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. The Company is developing compounds to treat various disorders including diabetes, human growth deficiencies and HIV/AIDS.

Detailed descriptions of the Company can be viewed on the Company's website [www.conjuchem.com](http://www.conjuchem.com).

### **Forward-Looking Statements**

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem's actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

**For more information, please contact:**

Lennie Ryer, CA  
Vice President Finance, CFO  
ConjuChem Inc.  
514-844-5558 ext 224  
ryer@conjuchem.com

Michael Polonsky  
Investor Relations  
416-815-0700 ext. 231  
416-815-0080  
mpolonsky@equicomgroup.com